News for Protalix BioTherapeutics, Inc. (PLX.TA)

Protalix BioTherapeutics (PLX) to present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference. The conference will take place on May 20, 20

PR NewswireCARMIEL, Israel, May 14, 2025 CARMIEL, Israel, May 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceut

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call Transcript May 9, 2025Protalix BioTherapeutics, Inc. misses on earnings expectations.

Release Date: May 09, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Protalix BioThera

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NPLX.A - Protalix Biotherapeutics IncQ1 2025 Protalix Biotherapeutics Inc Earnings CallMay 09,

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ETCompany ParticipantsMike Moyer – Investor RelationsDror...

Revenue: $10.1 million, significantly surpassing the estimated $21.60 million.Earnings Per Share (EPS): Reported a net loss of $0.05 per share, missing the est

PR NewswireCARMIEL, Israel, May 9, 2025 Company to host conference call and webcast today at 8:30 a.m. EDTCARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Prot

\n Protalix BioTherapeutics (PLX) to release Q1 2025 financial results on May 9, 2025. The company will host a conference call and webcast at 8:30 a.m. EDT

Key Takeaways: Protalix BioTherapeutics (PLX) reveals plans for a $100 million securities offering, leading to a post-market share increase of 1.7%. Anal

PR NewswireCARMIEL, Israel, March 24, 2025 CARMIEL, Israel, March 24, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharma

The global financial markets are experiencing heightened volatility, influenced by a confluence of economic and geopolitical factors.

Revenue from Selling Goods: $53 million for the year ended December 31, 2024, an increase of 31% from $40.4 million in 2023.Revenue from License and R&D Servic

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ETCompany ParticipantsMike Moyer - Investor Relations,...

PR NewswireCARMIEL, Israel, March 17, 2025 Company to host conference call and webcast today at 8:30 a.m. EDTCARMIEL, Israel, March 17, 2025 /PRNewswire/ -

PR NewswireCARMIEL, Israel, March 10, 2025 Company to host conference call and webcast at 8:30 a.m. EDTCARMIEL, Israel, March 10, 2025 /PRNewswire/ -- Prot

PR NewswireCARMIEL, Israel, Dec. 23, 2024 CARMIEL, Israel, Dec. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmace

PR NewswirePARMA, Italy and CARMIEL Israel, Dec. 9, 2024 Application to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered

Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Third Quarter 2024 Financial and Business Results Conference Call.